INTRODUCTION
Background : Human telomerase is a ribonucleoprotein polymerase, which synthesizes telomeric repeat sequences, and human telomerase reverse transcriptase (hTERT) has been identified as the catalytic subunit, as well as the rate-limiting component, of telomerase. In this study, we attempted to identify the modulators of telomerase, and to determine the molecular mechanisms underlying cisplatin-induced apoptosis.
Methods : To determine the role of telomerase in cisplatin-induced apoptosis, we measured telomerase activity and analyzed apoptosis using PI and trypan blue staining. Also, we inhibited the caspase activations using Z-VAD-fmk to analyze the effects on expression of hTERT protein. Finally, we induced the transient co-expression of the Bcl-2 and Bak genes in HEK293 cells, and then, the telomerase activity and expression of hTERT were evaluated.
Results : In the Bcl-2-overexpressing HeLa cells, telomerase activity was more enhanced, and cell death was reduced to 40-50% that of the mock controls. This finding suggests that Bcl-2-induced telomerase activity exerts an antiapoptotic effect in cisplatin-induced death. As caspase activation was inhibited via Z-VAD-fmk, the hTERT protein was recovered in the mock controls, but not in the Bcl-2-overexpressing cells. This suggests that the expression of hTERT can be regulated by caspases, but Bcl-2 was located within the upstream pathway. Moreover, when the Bcl-2 and Bak genes were co-transfected into the HEK293, both telomerase activity and hTERT protein were prominently reduced.
Conclusions 
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thereby allowing for the maintenance of genomic integrity. Human telomerase is comprised of telomerase reverse transcriptase (hTERT), and telomerase RNA component (hTR), as well as some associated factors which regulate the catalytic activity of telomerase [1, 2] . Recent findings have revealed that telomerase confers an additional function required for tumorigenesis, which is independent of its ability to maintain the telomere [3] . Additionally, telomerase contributes to the installation of an immortal cell phenotype via the prevention of apoptosis and may also perform a significant function in cellular resistance against anticancer drugs [4] [5] [6] [7] [8] .
In previous reports, the suppression of telomerase enzyme activity promotes apoptosis in neuronal cells [9] , germ cells [10] , and thymocytes [11] , whereas the overexpression of hTERT prevents apoptosis via interference with a pre-mitochondrial step in the cell death cascade [12] [13] [14] . Enhancements of telomerase activity via Bcl-2 gene overexpression have also been detected in cervical carcinoma, HeLa, and colorectal carcinoma DiFi cells [15] . However, this phenomenon, with the exception of the known possibility of a correlation between Bcl-2 and telomerase in cancer progression. For example, in high-grade non-Hodgkin lymphoma, high expression levels of hTERT mRNA may be related to shorter survival, and telomerase activity has been shown to be affected by the expressions of Bax and Bak [16] . However, the molecular mechanisms underlying the interactions between telomerase and these regulators remain unclear, despite the extensive efforts of a number of research groups that have attempted to dissect such mechanisms.
In this study, we focused on the functions of telomerase beyond reverse transcriptase in cancer progression. In an effort to identify the modulators of telomerase, we utilized an in vitro cisplatin (cis-diammine-dichloro-platinum II)-induced apoptosis system. 
MATERIALS AND METHODS

Cell culture
Antibodies and reagents
Anti-Bcl-2 monoclonal antibody (C-2) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and the anti-Bak monoclonal antibody was purchased from BD Biosciences (BD PharMingen, San Diego, CA, USA).
Rabbit anti-hTERT polyserum was acquired from Merck Biosciences (Calbiochem, La Jolla, CA, USA), and the broad caspase inhibitor (Z-VAD-fmk) was acquired from Promega (Promega, Madison, WI, USA). All other reagents used in this study were purchased from Sigma (St.
Louis, MO, USA) unless otherwise indicated.
Cytotoxicity Assay
To determine the role of telomerase in the programming of apoptotic death, we analyzed the cytotoxic effects of 
Construction of expression vectors and transfection
Wild-type Bcl-2 cDNA was generously provided by the Laboratories of Anticancer Research (KRIBB, Daejeon, Korea), and the Bcl-2 cDNA fragment was cloned into pcDNA3-neomycin (Invitrogen, Carlsbad, CA, USA). The pME18s-human Bak plasmid was kindly provided by the Genome Research Center (KRIBB). The fragment of human bak cDNA was transferred to the pCMV Tag plasmid (Invitrogen), and these constructs were verified via DNA sequence analysis. The transient transfection of HeLa or HEK293 with Bcl-2 and/or Bak plasmids was conducted using Lipofectamine/Plus reagent (Invitrogen), in accordance with the manufacturer's instructions. After 24 hr of incubation, cisplatin was administered, after which the samples were incubated for an additional 24 hr.
Telomeric repeat amplification protocol (TRAP) assay
Telomerase activity was measured using a TRAPeze kit The radioactive TRAP products were separated on 12.5% neutral polyacrylamide gel, then autoradiographed. 
Flow cytometry analysis of apoptosis
Trypan blue staining
The cells were stained with trypan blue (Sigma) and were counted using a hemocytometer. The percentage of cell death was expressed as the ratio of the number of trypan blue-permeable cells to the total cell count (trypan blue-permeable cell number/total cell number).
Western blot analysis
For Western blot analyses, the cisplatin-treated or transfected cells were lysed in a lysis buffer (20 mM Tris, pH 7.4, 2 mM EDTA, 150 mM sodium chloride, 1 mM sodium deoxycholate, 1% Triton X-100, 10% glycerol, 1 mM PMSF, 5 g/mL aprotinin, and 10 g/mL leupeptin), and the protein concentrations were determined using a BioRad protein assay kit (BioRad); 50-150 g of protein was subjected to 12-15% SDS-PAGE and transfered onto PVDF membranes (Hybond-P, Amersham Biosciences, Buckinghamshire, England). Subsequently, the membranes were incubated for 2 hr at room temperature in a 5% skim milk solution, then probed overnight at 4℃ with the appropriate primary antibodies. The bound antibodies were then visualized using a suitable secondary antibody conjugated with horseradish peroxidase, using enhanced chemiluminescence reagents (ECL, Amersham Biosciences).
RESULTS
Telomerase plays an antiapoptotic role in cisplatininduced cell death
Cisplatin inhibited the viability of HeLa cells dose-dependently (Fig. 1A) , and telomerase activity was transiently increased as the consequence of cisplatin treatment, but its activity with regard to Bcl-2 expression was enhanced to a greater degree than that of controls (Fig. 1B) . Therefore, we concluded that the enhanced activity effected by the expression of Bcl-2 also affected cisplatin-induced cell death, and the phenotype of cell death was determined via staining with propidium iodide (Fig. 1C ) or trypan blue (Fig. 1D ). As shown in Fig. 1C , apoptotic cell death was reduced to 40-50% in the Bcl-2 overexpressed cells as compared to the mock controls, and the trypan blue staining data was similar to that of the PI staining data (Fig.   1D ). In conclusion, telomerase activity is closely associated with cisplatin-induced cell death, and the enhanced activity affected by Bcl-2 exerts an anti-apoptotic effect.
TERT expression was dependent on caspase activation in cisplatin-induced cell death
As shown in Fig. 2 , about a two-fold increase in the quantity of hTERT protein was recovered as the result of Z-VAD-fmk inhibition in the mock control, but no change was detected in the Bcl-2 overexpressed cells. This finding suggests that the expression of hTERT was dependent upon the activation of caspase, but not on Bcl-2, which was located within the upstream pathway.
Co-expressions of Bcl-2 and Bak modulate the telomerase activity and TERT expression
In order to elucidate the interactions between wild type Bcl-2 and pro-apoptotic Bak on the function of telomerase, we transiently co-transfected a pcDNA-neo plasmid encoding for wt Bcl-2, or a pCMV Tag-neo plasmid encoding for Bak or control vectors, into the HEK293 cells. As shown in Fig. 3A , telomerase activity was found to be increased slightly by Bak expression, just as can be seen with cisplatin treatment in Fig. 1B . However, in case Bcl-2 and Bak were co-expressed at the same level, telomerase activity was reduced markedly. Evidently, hTERT protein was decreased to a greater degree on the Western blots than was seen in the vector control cells. Also, Bcl-2 protein expression was affected by Bak expression, but not Bak. The targeting of Bcl-2 by Bak may have an influence on the expression of hTERT (Fig. 3B) . Therefore, our findings suggest that both telomerase activity and hTERT expression may be regulated via intracellular Bcl-2 expression, and that this can be regulated in turn by the interactions occurring between Bcl-2 and Bak.
DISCUSSION
In an effort to identify the modulators of telomerase in the progression of cancers, we utilized a cisplatin-induced Currently, in order to inhibit telomerase, a variety of strategies have been adopted, including the introduction of TERT antisense oligomer [19, 20] , G-quadruplex-interactive agents [21, 22] , or small interference RNA [23] . In this study, we hypothesized that the targeting of the signaling modulators of telomerase might induce apoptosis in cancer cells. Therefore, we transiently overexpressed Bcl-2 cDNA in HeLa cervical cancer cells. The telomerase activity and apoptotic cell death induced by Bcl-2 were measured and evaluated (Fig. 1B-D) . As shown in Fig. 1B , telomerase activity was augmented by cisplatin signals, but Bcl-2 expression enhanced its activity prominently. This suggests that telomerase activity may be more closely associated with cisplatin-induced apoptosis, and also exert an antiapoptotic effect.
Next, to determine in which caspase proteins affect telomerase function, we inhibited caspase activations via the application of Z-VAD-fmk. The expression of hTERT, the catalytic subunit of telomerase, was recovered markedly; however, no change was observed in the Bcl-2-overexpressing cells (Fig. 2) . Thus, we conclude that telomerase activation is located downstream of the caspases, even though Bcl-2 existed in the upstream signal pathway, and also that the HeLa cells in our study underwent a cas- pase-dependent cell death as the result of cisplatin administration (data not shown). Previous reports have suggested that the ratio between anti-and pro-apoptotic proteins is the primary determinant of survival or cell death [24] .
Therefore, we co-transfected both Bcl-2 and Bak genes into HEK293 cells, and measured both telomerase activity and hTERT expression. The co-expressions of both genes at the same ratio resulted in a reduction in the telomerase activity and hTERT expression. Indeed, the expression patterns of hTERT and Bcl-2 were found to be quite similar (Fig. 3) . These findings suggest that the antiapoptotic effects of Bcl-2 were blocked in a reciprocal fashion by Bak expression. The interaction of Bcl-2 with Bak can modulate both telomerase activity and TERT expression, and can then regulate the apoptotic process. 
